Pharmacyclics Inc

Pharmacyclics — Technical Presentation (December 2011)

20 slides from Pharmacyclics's technical presentation, Dec 14, 2011

  1. Slide 1: Disclosures

    Disclosures Micwaet (LuHUA) WANG, MD RESEARCH FUNDING: Pharmacyclics, Celgene, Millennium, Norvatis, Onyx EMPLOYEE: N/A STOCKHOLDER: N/A CONSULTANT: None SCIENTIFIC ADVISORY BOARD: None

  2. Slide 2: PCI-32765 Highly Active As Single-Agent Therapy in Previously-Treated MCL

    The Bruton’s Tyrosine Kinase Inhibitor PCI-32765 is Highly Active As Single-Agent Therapy in Previously- Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial Micuaet (LuHuA) Wane, MD1, Peter MARTIN, MD, Kristie A. BLum, MD3, BRAD S. KAHL, MID4, LaurEN S. MAEDA, MIDS, RANJANA A

  3. Slide 3: Bruton's Tyrosine Kinase (BTK)

    Bruton’s Tyrosine Kinase (BTK) A critical kinase for lymphoma cell survival and proliferation B cell receptor * B-cell antigen receptor (BCR) signaling is required for tumor expansion and proliferation * Bruton's tyrosine kinase (BTK) is an essential element of the BCR signaling pathway * Inhibitors

  4. Slide 4: PCI-32765: First-in Class Inhibitor of BTK

    PCI-32765: First-in Class Inhibitor of BTK * Forms a specific and irreversible bond with cysteine-481 in BTK ° AY * Highly potent BTK inhibition at IC., = 0.5 nM * Orally administered with once daily dosing resulting in 24-hr target i \ + teas Ly Pa inhibition O * Blocks mantle cell migration and Ni

  5. Slide 5: Study Rationale

    Study Rationale In the Phase I, first-in-human, dose escalation study of PCI- 32765 56 patients with recurrent B-cell malignancies enrolled (including 9 with MCL) Toxicity was modest and MTD not reached Pharmacodynamic studies revealed complete BTK active-site occupancy at doses of 2.5 mg/kg and abo

  6. Slide 6: Study Design: PCYC-1104-CA

    Study Design: PCYC-1104-CA Multi-center, open-label, phase II single-agent study of PCI-32765 in two patient populations with relapsed or refractory Mantle Cell Lymphoma (MCL) Treatment: 560 mg PO daily until progression (cycle = 28 days) Objectives: To determine the response rate, duration of respo

  7. Slide 7: Early Analysis of an Ongoing Trial

    Early Analysis of an Ongoing Trial * Pharmacyclics study database from investigators as of October 25, 2011 * Enrolled population: 68 * Safety population (>1 cycle): 61 * Efficacy (response rate) population patients had at least one post-baseline tumor assessment: 51 * Bortezomib-naive: n=31 * Borte

  8. Slide 8: Subject Eligibility

    Subject Eligibility Pathologically confirmed MCL, with overexpression of cyclin D1 or t(11;14), and measurable disease on imaging Failure to achieve at least partial response (PR) with, or documented disease progression after, most recent treatment regimen At least 1, but no more than 5, prior treat

  9. Slide 9: Patient Characteristics

    Patient Characteristics Bortezomib-Naive | Bortezomib-Exposed i =) as ul Age: Medial Range: ae See on oe ae an Gender: Male 31 (76) 23 (85) 54 (79) Time from Initial Diagnosis, # (%) <3 yrs to 1% dose 20 (49) 6 (22) 26 (38) 23 yrs to 1% dose 21 (51) 21 (78) 42 (62) ECOG Status: 0 24 (59) 13 (48) 37

  10. Slide 10: Patient Characteristics

    Patient Characteristics Bortezom e Total (N=41) (N=68) Prior high intensity therapy, # (%) HyperCVAD Stem cell transplant 17 (41) 11 (41) 28 (41) Platinum-salvage therapy 5 (12) 2(7) 7 (10) 2(5) 0(0) 2(3) MIPI Score, # (%) Low risk 7(17) 3(11) 10 (15) Intermediate risk 16 (39) 10 (37) 26 (38) High r

  11. Slide 11: Patient Disposition

    Patient Disposition Bortezomi jaive | Bortezomib-Exposed Total (N=41) (N=27) (N=68) Time on Study (mos), # N 36 25 61 Median 37 37 37 Range 0.9-7.0 0.7-7.5 0.7-7.5 Patients Still on Study 29 (71) 19 (70) 48 (71) Treatment , # (%) Patients Discontinued 12 (29) 8 (30) 20 (29) Treatment , # (%) Primary

  12. Slide 12: Common Non-Hematologic AEs

    Common Non-Hematologic AEs (Events in > 10% of Patients Regardless of relationship to PCI-32765) rice i. Diarrhea i) Dzinss oysones Edema peripheral a Mucosal inflammation [SS Maia Rash i! Vomiting IN) a Abdominal Pain Grade 1 Grade 2 Grade 3 ™Grade 4

  13. Slide 13: Grade 3/4 Hematologic Toxicity

    Grade 3/4 Hematologic Toxicity (regardless of relationship to PCI-32765) Total ars Grade 3/4 Hematology toxicity’ (n=61) Grade3 Grade 4 Neutropenia 2% 3% Febrile neutropenia 3% 0% Anemia 3% 0% Thrombocytopenia 3% 0% Pancytopenia 0% 2% ‘Reported as Adverse Events

  14. Slide 14: Best Response

    80% 60% 40% 20% 0% 71% 16% 13% BTZ-naive (n=31) Best Response 65% «ll (n=20) 69% Total (n=51)

  15. Slide 15: Rapid Nodal Response Accompanied by Compartmental Shift

    Rapid Nodal Response Accompanied by “Compartmental Shift” of CD19/CD5+ B-cells Lymphocyte Count 200% H a 180% : i 100% -- 6 e ry Zz 50% . 7 SESIF FFE IS Day 4 Day 8 cos ———_> cos ——"_5 ésis SS Chang, D et al. Proc ASH 2011 Abstract 954, Tuesday 8:45 Rm SAB

  16. Slide 16: Best Response by Patient Characteristics

    Best Response by Patient Characteristics on] |All Patients — | 35/51 69 | | Bulky Disease 4/7 57 Refractory Yes 14/21 67 No 21/30 70 Prior cancer treatments <3 regimens 23/30 77 |_ 23 regimens 12/21 57 Prior high intensity therapy Yes | 22/31 71 | No 13/20 65 i MIPI Score: Low Risk 6/8 75 Intermedia

  17. Slide 17: Time on Study and to Best Response

    Time on Study and to Best Respon Time to first response Time to next response CR —=PR

  18. Slide 18: Time on Study by Best Response

    Time on Study by Best Response ——— -_ CR — PR == Stable Disease fe | | 6 7 8 *Patients off study Months

  19. Slide 19: Conclusions

    Conclusions + PCI-32765, a selective irreversible inhibitor of BTK, induced a very high response rate as a single oral agent for relapsed or refractory MCL. * PCI-32765 is associated with a favorable safety profile. * There was no significant myelosuppression. * This is an ongoing study and accurate

  20. Slide 20: Acknowledgement

    Acknowledgement All the patients and their families who participated in the study. Colleagues from all the clinical centers Colleagues from Pharmacyclics.

Pharmacyclics — Technical Presentation (December 2011) on 6ix